ARS Pharmaceuticals Inc

SPRY is in a confirmed Stage 4 decline with medium-term bearish bias reinforced by an active Support Failure pattern. Price remains below declining 9-, 21-, and 50-period EMAs, with rallies consistently rejected. No mean-reversion eligibility is present, and speculative execution favors an immediate Sell Now into resistance near the broken support cluster.

• ↑Q1 2026 revenue $22.7M; NEFI U.S. net sales $17.5M, prescriptions tripled YoY.
• ↑90% commercial coverage with 57% accessible without prior authorization.
• ↓Q3 2025 net loss $51.2M; SG&A expenses of $230M weigh on profitability.